Oxfordshire Clinical Commissioning Group
Formulary
 
back
8 Malignant disease and immunosuppression
08-02-04 Interferon beta

Interferon Beta-1a Avonex®
Formulary

For treating multiple sclerosis as per NICE TA527. 

Funded by specialised commissioning.

APCO July 2018.

Link  Commissioning Policy - Multiple Sclerosis
Link  MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF
Interferon Beta-1a Rebif®
Formulary

For treating multiple sclerosis as per NICE TA527.

Funded by specialised commissioning. 

APCO July 2018.

Link  Commissioning Policy - Multiple Sclerosis
Link  MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF
Interferon Beta-1b Extavia®
Formulary

For treating multiple sclerosis as per NICE TA527.

Funded by specialised commissioning.

APCO July 2018.

Link  Commissioning Policy - Multiple Sclerosis
Link  MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF
Interferon Beta-1b Betaferon®
Non Formulary

 For treating multiple sclerosis as per NICE TA527.

APCO July 2018. 

Link  Commissioning Policy - Multiple Sclerosis
Link  MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Black View adult BNF  View SPC online  View childrens BNF
Peginterferon Beta-1a Plegridy®
Non Formulary

For multiple sclerosis.

Not routinely commissioned by NHS England. IFR approval required.


Black View adult BNF  View SPC online  View childrens BNF  HCD